Virtual in vivo biopsy map of early prostate neoplasm in TRAMP mice by MRI

Prostate

Volumn 69, Issue 5, 2009, Pages 449-458

  Kiss, Pal ^a   Eltoum, Isam Eldin ^b   Suranyi, Pal ^a   Zeng, Huadong ^b   Simor, Tamas ^a   Elgavish, Ada ^c   Elgavish, Gabriel A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Contrast agent; Early cancer detection; MRI; PIN; TRAMP

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM 1,8 DIOXOTRIETHYLENETETRAAMINE N,N,N',N' TETRAACETIC ACID; UNCLASSIFIED DRUG; GADOLINIUM N (2 BUTYRYLOXYETHYL) N' (2 ETHYLOXYETHYL) N,N' BIS(N'',N'' BIS(CARBOXYMETHYL)ACETAMIDO) 1,2 ETHANEDIAMINE; GADOLINIUM N-(2-BUTYRYLOXYETHYL)-N'-(2-ETHYLOXYETHYL)-N,N'-BIS(N'',N''-BIS(CARBOXYMETHYL)ACETAMIDO)-1,2-ETHANEDIAMINE; ORGANOMETALLIC COMPOUND; PENTETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; BIOPSY; COMPUTER INTERFACE; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ANIMALS; BIOPSY; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; USER-COMPUTER INTERFACE;

EID: 61949131852     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20880     Document Type: Article

References (31)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26. (Pubitemid 24035713)
2. Feroze-Merzoug F, Schober M, Chen Y. Molecular profiling in prostate cancer. Cancer Metastasis Rev 2001;20:165-171. (Pubitemid 34595266)
3. Fleshner N, Fair W. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997;157:556-558. (Pubitemid 27026837)
4. Cher M, Chew K, Rosenau W, Carroll P. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995;26:87-93.
5. Dhom G. Epidemiologic and morphogenetic aspects of prostate cancer. Urologe A 1991;30:3-4.
6. Carter H, Coffey D. The prostate: An increasing medical problem. Prostate 1990;16:39-48. (Pubitemid 20127957)
7. Kiss P, Lenard L, Simor T, Forder J, Mentor-Marcel R, Elgavish A, Elgavish GA. MR Imaging As a Tool to Monitor Prostate Tumor Growth in Mice with Mutant p53 Gene. In Joint Annual Meeting of ISMRM-ESMRMB, Glasgow, Scotland, United Kingdom, 2001.
8. Haese A, Graefen M, Huland H, Lilja H. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Curr Urol Rep 2004;5:231-240.
9. Caplan A, Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002;117(Suppl):S104-S108.
10. Conrads T, Veenstra T. The utility of proteomic patterns for the diagnosis of cancer. Curr Drug Targets Immune Endocr Metab Disord 2004;4:41-50. (Pubitemid 38854880)
11. Bostwick D, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-379. (Pubitemid 41646613)
12. Rajesh A, Coakley F. MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am 2004;12:557-579 vii. (Pubitemid 38980042)
13. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2004;62:140-147.
14. Noworolski S, Henry R, Vigneron D, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 2005;53:249-255. (Pubitemid 40171038)
15. Storaas T, Gjesdal K, Svindland A, Viktil E, Geitung JT. Dynamic first pass 3D EPI of the prostate: Accuracy in tumor location. Acta Radiol 2004;45:584-590. (Pubitemid 44112215)
16. Allen DJ, Hindley R, Clovis S, O'Donnel P, Cahill D, Rottenberg G, Popert R. Does body-coil magnetic-resonance imaging have a role in the preoperative staging of patients with clinically localized prostate cancer? BJU Int 2004;94:534-538.
17. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998;159:915-919. (Pubitemid 28106556)
18. Fritz-Hansen T, Rostrup E, Ring PB, Larsson HB. Quantification of gadolinium-DTPA concentrations for different inversion times using an IR-turbo flash pulse sequence: A study on optimizing multislice perfusion imaging. Magn Reson Imaging 1998;16:893-899. (Pubitemid 28499010)
19. Saab-Ismail NH, Simor T, Gaszner B, Lórand T, Szöllösy M, Elgavish GA. Synthesis and in vivo evaluation of new contrast agents for cardiac MRI. J Med Chem 1999;42:2852-2861. (Pubitemid 29370429)
20. Greenberg N, DeMayo F, Finegold M, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
21. Gingrich J, Barrios R, Morton R, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102. (Pubitemid 26304996)
22. Gingrich J, Barrios R, Foster B, Greenberg N. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-75. (Pubitemid 29259935)
23. Mentor-Morcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-6782.
24. Kaldoudi E, Williams SCR. Relaxation time measurements in NMR imaging. Part I: Longitudinal relaxation time. Concepts Magn Reson 1993;5:217-242.
25. Messroghli DR, Niendorf T, Schulz-Menger J, Dietz R, Friedrich MG. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magn Reson 2003;5:353-359. (Pubitemid 36569954)
26. Wechter WJ, Leipold DD, Murray ED Jr., Quiggle D, McCracken JD, Barrios RS, Greenberg NM. E-7869 (R-Flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-2208. (Pubitemid 30225184)
27. Wu G, Wang L, Yu L, Wang H, Xuan JW. The use of three-dimensional ultrasound micro-imaging to monitor prostate tumor development in a transgenic prostate cancer mouse model. Tohoku J Exp Med 2005;207:181-189. (Pubitemid 41601047)
28. Ozawa M, Yao V, Chanthery Y, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasquadini R, Arap W, McDonald DM. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 2005. (Pubitemid 41579956)
29. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
30. Zangos S, Eichler K, Engelmann K, Ahmed M, Dettmer S, Herzog C, Pegios W, Wetter A, Lehnert T, Mack MG, Vogl TJ. MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: Technique and preliminary results. Eur Radiol 2005;15:174-182. (Pubitemid 40109788)
31. Kasper S, Smith J. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004;172:12-19. (Pubitemid 41615031)